|
Name |
Cyperotundone
|
Molecular Formula | C15H22O | |
IUPAC Name* |
(1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-en-3-one
|
|
SMILES |
C[C@@H]1CC[C@@H]2CC3=C(C(=O)C[C@]13C2(C)C)C
|
|
InChI |
InChI=1S/C15H22O/c1-9-5-6-11-7-12-10(2)13(16)8-15(9,12)14(11,3)4/h9,11H,5-8H2,1-4H3/t9-,11-,15+/m1/s1
|
|
InChIKey |
GIGKXOAUYMWORB-OSQNNJELSA-N
|
|
Synonyms |
Cyperotundone; Cyperenone; 3466-15-7; (+)-Cyperotundone; (1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-en-3-one; Isopatchoulenone; DTXSID901316512; HY-N3004; s3303; CS-0022904; E88749; (3aR,4R,7R)-1,4,9,9-Tetramethyl-3,4,5,6,7,8-hexahydro-2H-3a,7-methanoazulen-2-one; 3H-3a,7-Methanoazulen-2(4H)-one, 5,6,7.alpha.,8-tetrahydro-1,4.alpha.,9,9-tetramethyl-; 3H-3a,7-Methanoazulen-2(4H)-one, 5,6,7,8-tetrahydro-1,4,9,9-tetramethyl-, (3aR,4R,7R)-; 3H-3a,7-Methanoazulen-2(4H)-one, 5,6,7,8-tetrahydro-1,4,9,9-tetramethyl-, [3aR-(3a.alpha.,4.beta.,7.alpha.)]-; 3H-3a,7-Methanoazulen-2(4H)-one, 5,6,7.alpha.,8-tetrahydro-1,4.alpha.,9,9-tetramethyl-, (+)-
|
|
CAS | 3466-15-7 | |
PubChem CID | 12308615 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 218.33 | ALogp: | 3.4 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 17.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.588 |
Caco-2 Permeability: | -4.821 | MDCK Permeability: | 0.00002530 |
Pgp-inhibitor: | 0.069 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.116 |
Blood-Brain-Barrier Penetration (BBB): | 0.128 | Plasma Protein Binding (PPB): | 93.59% |
Volume Distribution (VD): | 0.778 | Fu: | 8.12% |
CYP1A2-inhibitor: | 0.607 | CYP1A2-substrate: | 0.686 |
CYP2C19-inhibitor: | 0.91 | CYP2C19-substrate: | 0.902 |
CYP2C9-inhibitor: | 0.746 | CYP2C9-substrate: | 0.607 |
CYP2D6-inhibitor: | 0.069 | CYP2D6-substrate: | 0.46 |
CYP3A4-inhibitor: | 0.227 | CYP3A4-substrate: | 0.43 |
Clearance (CL): | 7.656 | Half-life (T1/2): | 0.294 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.092 |
Drug-inuced Liver Injury (DILI): | 0.066 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.051 | Maximum Recommended Daily Dose: | 0.669 |
Skin Sensitization: | 0.675 | Carcinogencity: | 0.109 |
Eye Corrosion: | 0.237 | Eye Irritation: | 0.922 |
Respiratory Toxicity: | 0.935 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC006062 | 0.429 | D0H1QY | 0.358 | ||||
ENC002989 | 0.400 | D0V8HA | 0.316 | ||||
ENC004785 | 0.377 | D0Q6NZ | 0.282 | ||||
ENC002355 | 0.377 | D0G8BV | 0.259 | ||||
ENC002356 | 0.371 | D0U3GL | 0.253 | ||||
ENC003477 | 0.365 | D09NNA | 0.250 | ||||
ENC001408 | 0.365 | D04GJN | 0.247 | ||||
ENC002058 | 0.354 | D04DJN | 0.244 | ||||
ENC002195 | 0.354 | D0K7LU | 0.243 | ||||
ENC002941 | 0.343 | D0D2VS | 0.238 |